15h
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, ...
How the DoD funding move ties into Humacyte’s investment story The latest U.S. Department of Defense appropriations and authorization bills set aside funding to assess biologic vascular repair ...
The recently passed federal defense budget for 2026 includes dedicated funding for the use of bioengineered blood vessels ...
Humacyte (HUMA) added ~27% on Monday after the Durham, North Carolina-based biotech said that the U.S. Congress has passed ...
Zacks Investment Research on MSN
Humacyte, Inc. (HUMA) exceeds market returns: Some facts to consider
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.02, moving +2.24% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.54%. At the same time ...
DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
Humacyte, Inc. (HUMA) concluded the recent trading session at $1.05, signifying a -13.93% move from its prior day's close.
Investing.com -- Humacyte Inc (NASDAQ:HUMA) stock surged 11.4% on Monday after the company announced that the U.S. Department of Defense’s FY 2026 Appropriations Act includes dedicated funding to ...
DURHAM – Humacyte, which officially merged with the special purpose acquisition company Alpha Healthcare Acquisition Corp. after shareholders of the SPAC voted to approve the move last week, is ...
Editor’s note: LimeLight is a new feature from WRAL TechWire offering another means of publishing noteworthy news. Be sure to check out more LimeLight worthy news at this link. DURHAM – Alpha ...
DURHAM, N.C., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...
The options for patients needing new blood vessels come with tradeoffs. Harvesting a vein requires a second surgery and additional recovery time. Synthetic implants can be readily pulled off the shelf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results